Lilly selling half-price version of popular Humalog insulin

A half-price version of Eli Lilly's popular Humalog insulin is now available, following the company's promise in March to offer diabetics a more affordable option amid fierce criticism of soaring insulin prices.

Lilly, one of the three top makers, said Wednesday that it has begun selling its own generic version of Humalog U-100 under the chemical name insulin lispro.

The Indianapolis drugmaker said insulin lispro will cost $137.35 per vial, or $265.20 for a package of five KwikPens, an easier-to-inject option.

Those figures are half the list price Lilly charges for Humalog. The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.

Lilly said the biggest savings will go to patients who are uninsured, have high-deductible health insurance or have Medicare Part D plans.

Insurers generally pay drugmakers far less than the list price, but many patients must pay a percentage of the list price or the full amount until they meet their 's annual deductible.

Because insulin lispro is identical to Humalog, pharmacists will be able to substitute the half-price generic. However, Lilly noted that some patients will still pay less for Humalog than insulin lispro, depending on their insurance plan.

Patients with diabetes don't produce enough insulin to control their , or their body uses insulin in efficiently, forcing them to inject the hormone, usually several times a day.

The average insulin price nearly tripled from 2002 through 2013, and have risen 10% or more a year since then, forcing many diabetics to ration their insulin. Some have ended up in hospitals and a few have died as a result, which has led to congressional hearings on the issue.

© 2019 The Associated Press. All rights reserved.

Citation: Lilly selling half-price version of popular Humalog insulin (2019, May 22) retrieved 5 March 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Lilly to sell cheaper version of top-selling insulin Humalog


Feedback to editors